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Abstract  
The objective of this analysis was to evaluate mortality among a cohort of 24,865 
capacitor-manufacturing workers exposed to polychlorinated biphenyls (PCBs) at plants in 
Indiana, Massachusetts, and New York and followed for mortality through 2008.  Cumulative 
PCB exposure was estimated using plant-specific job-exposure matrices.  External comparisons 
to US and state-specific populations used standardized mortality ratios, adjusted for gender, race, 
age and calendar year.  Among long-term workers employed 3 months or longer, within-cohort 
comparisons used standardized rate ratios and multivariable Poisson regression modeling.  
Through 2008, more than one million person-years at risk and 8749 deaths were accrued.  
Among long-term employees, all-cause and all-cancer mortality were not elevated; of the a 
priori outcomes assessed only melanoma mortality was elevated.  Mortality was elevated for 
some outcomes of a priori interest among subgroups of long-term workers: all cancer, intestinal 
cancer and amyotrophic lateral sclerosis (women); melanoma (men); melanoma and brain and 
nervous system cancer (Indiana plant); and melanoma and multiple myeloma (New York plant).  
Standardized rates of stomach and uterine cancer and multiple myeloma mortality increased with 
estimated cumulative PCB exposure.  Poisson regression modeling showed significant 
associations with estimated cumulative PCB exposure for prostate and stomach cancer mortality.  
For other outcomes of a priori interest – rectal, liver, ovarian, breast, and thyroid cancer, non-
Hodgkin lymphoma, Alzheimer disease, and Parkinson disease – neither elevated mortality nor 
positive associations with PCB exposure were observed.  Associations between estimated 
cumulative PCB exposure and stomach, uterine, and prostate cancer and myeloma mortality 
confirmed our previous positive findings.   
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Introduction 
From 1929 to 1977, 209 polychlorinated biphenyl (PCB) congeners were produced 
commercially in the United States.  Mixtures of PCBs were used widely in industry [Robertson 
and Ludewig 2011; Robertson and Ruder 2010] and persist in humans and in the environment 
[Hopf, et al. 2009a].  Increasing concern about potential health and environmental risks led to a 
1977 ban on PCB production and distribution in the United States and a 2004 ban on PCB 
production in 151 signatory countries [United Nations Environment Programme 2004].  In 2013 
the International Agency for Research on Cancer (IARC) classified PCBs  as  definite human 
carcinogens[Lauby-Secretan, et al. 2013].  
Thirty-five years after their use was banned in the United States PCBs are still a potential 
occupational and environmental exposure for those who repair, maintain, or remove capacitors 
and transformers containing PCBs and for the general public, as well as for the former workers 
whose decades of internal exposure to PCBs continue [Beyer and Biziuk 2009].  The National 
Institute for Occupational Safety and Health (NIOSH) has assembled a cohort of workers who 
manufactured capacitors using PCBs as a dielectric fluid at plants in Indiana (1957-1977) 
[Ruder, et al. 2006], and Massachusetts (1939-1976) and New York (1946-1977) [Prince, et al. 
2006].  Dielectric fluid formulations (i.e., different commercial products containing some of the 
209 PCB congeners) varied across time and across the plants (see Table 1).   
Previous reports utilized different requirements for eligibility (one day vs. 90 days) and 
considered the Indiana plant separately from the Massachusetts and New York plants for most 
causes of death [Brown 1987; Brown and Jones 1981; Prince, et al. 2006; Ruder, et al. 2006; 
Sinks, et al. 1992], but jointly for breast cancer incidence [Silver, et al. 2009] and 
neurodegenerative disease mortality [Steenland, et al. 2006].   
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The rationale for this study was that by combining the three largest US capacitor 
manufacturing cohorts and incorporating ten additional years of mortality experience, previous 
findings and hypothesized relationships could be re-evaluated with greater statistical power due 
to more workers, longer follow-up, and the integration of the three cohort exposure assessments. 
The current study extends vital status follow-up an additional ten years through 2008 and 
includes all workers from the three plants with one day or more of employment during the period 
when PCBs were in use, but focuses on workers employed 3 months or more.  Job-exposure 
matrixes developed for the three plants were used to estimate cumulative PCB exposure for each 
worker.  The primary purpose was to investigate further the relationship between estimated 
cumulative PCB exposure and mortality outcomes, particularly among long-term workers 
employed for three months or longer.  Outcomes of a priori interest included causes of death 
with increased risks originally observed in the subcohorts followed through 1998, including 
hormone-related cancers (i.e., prostate, breast, uterine, and ovarian), multiple myeloma, 
melanoma, brain and nervous system cancer, stomach cancer, intestinal cancer, and 
neurodegenerative diseases.  Other a priori hypotheses were that PCB exposure would affect all-
cause mortality, all-cancer mortality, and, specifically, rectal cancer, biliary passages, liver, and 
gall bladder cancer, and non-Hodgkin lymphoma, outcomes for which other studies indicated 
increased risks [Brown 1987; Brown and Jones 1981; Rothman, et al. 1997].  More recent results 
have motivated the addition of thyroid cancer to the a priori list [Mallin, et al. 2004; Yard, et al. 
2011].  Including all the workers in one analysis and adding ten years of vital status follow-up 
increases the power of the study.   
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Materials and methods 
Cohort 
The cohort included all workers employed at least one day at any of the plants.  Records 
were maintained for 26,588 workers; however, those not employed during the years PCBs were 
used or employed less than one day were excluded from the final PCB cohort of 25,062 workers.  
Demographic data sources included work histories and plant records.  Records for the New York 
and Massachusetts workers were originally microfilmed in 1977, although only the 2588 workers 
considered highly exposed were included in the first analyses [Brown 1987; Brown and Jones 
1981].  The cohort was expanded to include all exposed workers at the New York and 
Massachusetts plants using these microfilmed records, which were verified against Internal 
Revenue Service (IRS) Employer’s Quarterly Earnings Reports for the New York plant [Prince, 
et al. 2006].  Records for the Indiana workers were microfilmed and data-entered in 1989 [Sinks, 
et al. 1992].   
Exposure assessment 
Exposure data sources included company and NIOSH surveys of the plants and plant 
records.  The exposure assessment used previously created plant-specific semi-quantitative job-
exposure matrices (JEMs) that are described in detail in [Hopf, et al. 2013; Hopf, et al. 2009b; 
Hopf, et al. 2010] and briefly here.  All jobs were categorized based on PCB exposure intensity 
and frequency, and qualitatively ranked for inhalation and dermal exposure.  For inhalation 
exposure intensity, air concentration data permitted assignment of exposure units (ppm), but the 
lack of historical dermal exposure measurements resulted in a unitless measure of dermal 
exposure intensity.  For each job category the product of intensity and frequency (fraction of day 
exposed) was calculated.  Inhalation and dermal JEMs were modified for earlier and later eras 
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(the former with estimated 20% higher exposure).  Since dermal exposures account for a 
significant proportion of total PCB exposure [Fishbein 1982], a combination JEM averaging 
inhalation and dermal (1:1) scores was used to estimate PCB exposure for each job by era.  
Detailed work histories available for each worker were used to estimate cumulative PCB 
exposure, based on plant, department, job title, and the era-specific combination JEM, and 
expressed in unit-days or unit-years of exposure (but the “unit” was undefined). 
Vital status follow-up 
Vital status was originally determined through 1982 for the New York and Massachusetts 
cohorts using records from the Social Security Administration (SSA) Death Master File, state 
motor vehicle registration and vital statistics offices, the US Postal Service, and, after 1979, the 
National Death Index (NDI) [National Center for Health Statistics 2007] [Brown 1987; Brown 
and Jones 1981].  Vital status was determined through 1984 for the Indiana cohort using records 
from the SSA and the IRS [Sinks, et al. 1992].  For previous analyses [Brown 1987; Brown and 
Jones 1981; Sinks, et al. 1992], death certificates had been obtained for pre-1979 deaths and 
causes of death coded by a trained nosologist.  Subsequent vital status updates for all three 
subcohorts used the NDI [Prince, et al. 2006; Ruder, et al. 2006].   
For the present update, cohort member data were submitted to the NDI for determination 
of vital status through 2008, and NDI-Plus causes of death were obtained.  Any worker lost to 
follow-up before 1979 was classified ‘vital status unknown’ and considered alive until the date 
last observed (usually the date last employed).  All causes of death (NDI and death certificate-
based) were coded to the revision of the International Classification of Diseases (ICD) in effect 
at the time of death, and mapped to specific cause of death categories (described below).  This 
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study (HSRB 08-DSHEFS-02) has been approved by the NIOSH Human Subjects Review 
Board.  As a records study, it was exempted from informed consent requirements. 
Statistical analysis 
Mortality was evaluated using the NIOSH life table analysis system [Schubauer-Berigan, 
et al. 2011].  Analyses used US mortality rates for 92 (1940-2007) or 119 (1960-2007) cause of 
death categories [Robinson, et al. 2006] and three neurodegenerative causes of death: Alzheimer 
disease, amyotrophic lateral sclerosis (ALS), and Parkinson disease [Steenland, et al. 2006].  
Race- and gender-specific person years at risk (PYAR) were accumulated for each eligible 
worker across five-year age and calendar year intervals, beginning on the qualified date of first 
exposure, or the rate file begin date (January 1, 1940 or January 1, 1960), whichever was later, 
and ending with the date of death, the date last known alive, or the study end date (December 31, 
2008), whichever was earliest.  Cohort members with valid social security numbers known to be 
alive after January 1, 1979, when the NDI began, and not identified as deceased were assumed to 
be alive on December 31, 2008, as the sensitivity of the NDI is over 95% when social security 
numbers are available [Cowper, et al. 2002].  For each cause of death, PYAR were multiplied by 
the gender-race-age-calendar period referent rates and summed to yield an expected number of 
deaths.  The standardized mortality ratio (SMR) is the ratio of observed to expected deaths. The 
statistical significance of the SMR was determined by a two-tailed test based on the Poisson 
distribution and a 95% confidence interval (CI) was calculated based on exact (10 or fewer 
deaths) or approximate (more than 10 deaths) methods. 
Plant-specific analyses used state mortality rates (1960-2007) for the 119 cause of death 
categories.  State rates account for local conditions that can influence disease rates (e.g., the 
gradient of disease with latitude seen for some cancers [Foster, et al. 2008]).  A multiple-cause-
9 
of-death analysis considering all causes listed on the death certificates investigated possible 
excesses in nonmalignant diseases using US multiple cause referent rates (1960-2007) 
[Steenland, et al. 1992].  Because of the large number of short-term workers, and for 
comparability to previous updates, we conducted separate analyses of short-term (employment 
duration less than 3 months) and long-term (employment duration of 3 months or longer) 
workers.   
Within-cohort comparisons 
The distribution of estimated cumulative PCB exposure was highly right-skewed (range 
10 to 9.6×106 unit-days; median 3.2×104 unit-days); cutpoints at 40,000, 150,000, and 600,000 
unit-days defined quartiles with approximately equal numbers of deaths among long-term 
workers.  Among long-term workers, standardized rates were calculated for each quartile using 
the sum of all PYAR for each gender-race-age-calendar period stratum as the stratum weight.  
Directly standardized rate ratios (SRRs) were calculated for each exposure quartile relative to the 
lowest quartile and 95% CIs were calculated based on a Taylor series approximation of the 
variance [Rothman and Greenland 1998].  A test for a linear trend was performed based on a 
weighted regression of the standardized rates [Rothman, et al. 2008].  To account for potential 
latency, exposure lag periods of 10 and 20 years were evaluated for cancer outcomes.  Analyses 
that considered cumulative exposure excluded 515 workers with periods of unknown exposure 
who were included in the overall results. 
Relations between estimated cumulative PCB exposure and mortality were examined 
using Poisson regression modeling [Frome 1983] available in the GENMOD procedure in SAS 
(version 9.2, SAS Institute Inc., Cary, NC).  Regression models were performed among long-
term workers for prostate, uterine, ovarian, and stomach cancers and multiple myeloma because 
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a previous analysis of the Massachusetts and New York subcohorts found an exposure-response 
effect for these outcomes [Prince, et al. 2006].  Effect modification was evaluated for gender, 
race, and plant using the likelihood ratio test for interaction and confounding by gender, race, 
age, birth year, and plant, was evaluated using a change-in-estimate criterion of 10%.  In these 
models, estimated cumulative exposure was treated as either a categorical variable (5 categories 
based on quintiles of the exposure distribution among cases) or a continuous variable.  Several 
exposure transformations (identity, natural logarithm, and square root) were evaluated and the 
best-fitting model (based on Akaike’s information criterion (AIC) [Akaike 1979]) was reported.  
Exposure lag periods of 0, 5, 10, 15, and 20 years were evaluated and results of the best-fitting 
lag period (also based on AIC) were reported.  Collinearity among model predictors, evaluated 
for best fitting models using methods for generalized linear models, was not observed [Lesaffre 
and Marx 1993].   
In the Poisson regression models, age and birth year were centered at the median age at 
death and birth year among cases, so the model intercept estimates the logarithm of the 
background rate for an unexposed worker at the median age at death and birth year.  For some 
outcomes, variability in the estimated intercepts was observed with some models estimating 
implausibly low background rates.  For this reason, all model forms were re-evaluated using 
constrained models in which the intercept was specified to fix the background rate across 
models.   
In supplemental analyses, best fitting models were re-evaluated excluding workers with 
any time in a job category with potential for trichloroethylene (TCE) exposure (time in “setup 
and/or operate wet machines” or “setup and/or operate dry machines” at Indiana; in “degreaser” 
at Massachusetts; or in “degreasers and painters” at New York).  Analyses were conducted 
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excluding these solvent-exposed workers because they did not comprise a large enough group to 
be analysed separately.  Two-sided p<0.05 was considered statistically significant. 
 
Results 
After exclusions (n=197) for missing data, the final cohort of 24,865 workers contributed 
1,019,128 PYAR (Table 2).  Through 2008, 8749 cohort members (35%) had died.   
In the overall cohort, all-cause mortality was similar to the US population (8749 deaths, 
SMR 0.97, 95% CI 0.95-1.00), but all-cancer mortality was elevated (2602 cancer deaths, SMR 
1.05, 95% CI 1.01-1.09).  These results, based on the 1940-2008 time period, were similar to 
results based on the 1960-2008 time period (presented in Table 3).  As only 61 deaths occurred 
before 1960 and 119 category US and state rates are only available from 1960, we present here 
only results from 1960 on (8688 deaths).  For ease of comparison with previous results we 
present all categories for which 3 or more deaths occurred.   
Compared to the US population, mortality was not significantly elevated in the overall 
cohort for any individual outcome of a priori interest, although statistically significant increases 
were observed for all cancers combined, all cancers of the digestive organs and peritoneum 
combined, all respiratory cancers combined, and HIV-related disease (Table 3).  Furthermore, 
significant deficits were observed among all workers for alcoholism, heart diseases, digestive 
system diseases, symptoms and ill-defined conditions, injuries, suicide and homicide.  Similar 
results were observed (results not shown) when all causes listed on the death certificate were 
considered.   
The median duration of employment in the cohort was less than one year and short-term 
workers (less than 3 months of employment) comprised nearly one-third of the cohort.  Among 
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these short-term workers, all-cause and all-cancer mortality were elevated with excesses for 
pharyngeal, pancreatic, lung, and bladder cancers, HIV-related disease, dementia and Alzheimer 
disease, heart disease, and chronic obstructive pulmonary disease (Table 3).  Among long-term 
workers there was a significant increase in melanoma mortality (41 deaths, SMR 1.41, 95% CI 
1.01-1.91); elevations were not observed for other outcomes of a priori interest.  Mortality 
among long-term workers was significantly reduced for all causes combined, tuberculosis and 
HIV-related disease, mental, psychoneurotic, and personality disorders, and respiratory diseases, 
in addition to those categories with significant decreases in the cohort overall.  Additional 
analyses focused exclusively on the long-term workers. 
Table 4 shows mortality for a priori outcomes among long-term workers stratified by 
plant.  Using state rates, mortality was significantly elevated among long-term workers for two 
outcomes of a priori interest previously observed at the Indiana plant: melanoma (SMR 2.58, 
95% CI 1.38-4.42) and cancers of the brain and other parts of the nervous system (SMR 2.06, 
95% CI 1.20-3.29); two outcomes of a priori interest previously observed at the New York plant: 
melanoma (SMR 1.71, 95% CI 1.04-2.64) and multiple myeloma (SMR 1.74, 95% CI 1.08-
2.66); but for no outcomes at the Massachusetts plant.  
 All-cause and all-cancer mortality was significantly reduced among long-term workers at 
the Indiana plant, but not among long-term workers at the Massachusetts and New York plants. 
Table 5 shows mortality for a priori outcomes among long-term workers stratified by 
sex.  Compared to the US population, mortality was significantly elevated for long-term female 
workers for all cancers (SMR 1.06, 95% CI 1.00-1.13), intestinal cancer (SMR 1.23, 95% CI 
1.00-1.49), and ALS (SMR 1.90, 95% CI 1.09-3.09).  Among long-term male workers, all-cause 
mortality was significantly reduced (SMR 0.91, 95% CI 0.88-0.94) but melanoma mortality was 
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significantly elevated (SMR 1.59, 95% CI 1.06-2.28).  In both sexes, multiple myeloma 
mortality was elevated, but neither elevation was statistically significant.  While long-term male 
and female workers had comparable mean and median cumulative exposures in the 
Massachusetts subcohort, long-term female workers in the Indiana and New York subcohorts 
had lower mean and median cumulative exposures compared to male workers (results not 
shown).   
Among long-term workers, directly standardized mortality rates increased with quartiles 
of estimated cumulative PCB exposure for stomach and uterine cancer and multiple myeloma; 
but not for other a priori outcomes evaluated (Table 6).  Prostate cancer mortality was elevated 
in the highest quartile compared to the lowest quartile (SRR 2.11, 95% CI 1.08-4.13).  Similar 
results were observed for cancer outcomes when a 10- or 20-year lag period was applied (results 
not shown).   
Poisson regression models are summarized in Table 7.  For the outcomes evaluated 
(prostate, uterine, ovarian, and stomach cancers and multiple myeloma), the model with the best-
fitting lag period was reported although model fit did not vary much across lag periods (results 
not shown); plant was neither an effect modifier nor a confounder; age and birth year were 
positive confounders; and all but two cases were among Caucasians so confounding from race 
was not evaluated.  Prostate cancer mortality was significantly associated with estimated 20-year 
lagged (and log transformed) cumulative PCB exposure among long-term male workers 
(adjusted rate ratio (RR) 2.22 at 1000 unit-years, 95% CI 1.06-4.80); however, the RR was 
slightly reduced in the constrained intercept model (RR 1.73 at 1000 unit-years, 95% CI 1.08-
2.74).  Furthermore, prostate cancer mortality was significantly elevated in the highest exposure 
quintile relative to the lowest quintile.   
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Shorter lag periods provided the best fit for Poisson regression models of uterine (10-year 
lag period) and ovarian (5-year lag period) cancer mortality among long-term female workers; 
however, no significant associations were observed with estimated cumulative PCB exposure in 
any Poisson model evaluated for uterine or ovarian cancer.  Stomach cancer mortality among 
long-term workers was significantly associated with estimated 15-year lagged (and log 
transformed) cumulative PCB exposure (RR 4.79 at 1000 unit-years, 95% CI 1.83-13.3); 
however, the rate ratio was diminished, but remained statistically significant in the constrained 
intercept model.  A 10-year exposure lag period was best fitting for Poisson models of multiple 
myeloma mortality; however, multiple myeloma mortality was not significantly associated with 
estimated cumulative PCB exposure in any model evaluated.  Estimated rate ratios are 
graphically displayed in Figure 1 along with other model forms evaluated. 
Similar results were obtained for best-fitting models for prostate, uterine, and ovarian 
cancer and multiple myeloma (data not shown) when workers with any time in jobs with 
potential TCE exposure were excluded; however, for stomach cancer, the RR associated with a 
1000 unit-year increase (based on the natural log transformation) decreased to 3.49 (95% CI 
1.21-10.8) when workers potentially exposed to TCE were excluded.   
 
Discussion 
This update of our capacitor-manufacturing worker study, combining three subcohorts 
previously analyzed separately, adding ten years of vital status data, and focusing on long-term 
workers, confirmed and strengthened previous findings.  Mortality was elevated for some 
outcomes of a priori interest among subgroups of long-term workers: all cancer, intestinal cancer 
and amyotrophic lateral sclerosis (women); melanoma (men); melanoma and brain and nervous 
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system cancer (Indiana plant); and melanoma and multiple myeloma (New York plant).  Internal 
comparisons showed increasing rates of stomach and uterine cancer and multiple myeloma 
mortality with increasing estimated cumulative PCB exposure.  Poisson regression modeling 
showed significant associations with estimated cumulative PCB exposure for prostate and 
stomach cancer mortality.   
For other outcomes of a priori interest – rectal, liver, ovarian, breast, and thyroid cancer, 
non-Hodgkin lymphoma, Alzheimer disease, and Parkinson disease – neither elevated mortality 
nor positive associations with PCB exposure were observed.  Studies of mortality in cohorts 
occupationally exposed to PCBs have presented inconsistent findings.  Nine cohorts of electrical 
capacitor and transformer manufacturers have been studied to date (see supplemental table to 
[Ruder, et al. 2006]).  In some cases SMRs were elevated for one sex but not the other.  Excess 
deaths from particular cancers or other diseases have been reported, but there has not been 
consistency from cohort to cohort, or even within cohort across studies.  These inconsistencies 
might be related to differences in the exposure assessments, to differing procedures at different 
plants and in different eras, to differing properties and modes of action of the PCB congeners, 
and to these manufacturing facilities having used varying commercial mixtures of PCB 
congeners [AccuStandard Inc. 2012].   
In our study, the excess melanoma mortality among Indiana and New York workers, but 
lack of excess among Massachusetts workers, could be due to lifestyle factors, differences in the 
PCB mixtures used, occupational exposures other than to PCBs, or interplant differences in work 
practices (see Table 1 comparing the three plants).  The original study of the Indiana plant noted 
that PCB-exposed workers were at greater risk of skin effects, including chloracne and 
hyperpigmentation [Sinks, et al. 1992].  Several recent papers support an association of 
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melanoma and PCB exposure:  Behrens and colleagues observed an increased risk of uveal 
melanoma among men with occupational exposure to transformer or capacitor oils (odds ratio 
2.74, 95% CI 1.07-7.02) [Behrens, et al. 2010]; Gallagher et al. saw a dose-response effect for 
melanoma risk and plasma levels of PCBs (p for trend <0.001), comparing melanoma patients 
and controls [Gallagher, et al. 2011]; and Loomis and colleagues reported increased melanoma 
risk among electrical utility workers exposed to PCBs [Loomis, et al. 1997].  A review (which 
included the original study of the Indiana cohort [Sinks, et al. 1992]) of non-solar occupational 
risk factors for melanoma found increased risks for workers in the electric and electronic 
industry [Fortes and de Vries 2008].  In 2013 an International Agency for Research on Cancer 
Working Group concluded that there was sufficient evidence for human cancinogenity of PCBs, 
based on the analyses of melanoma and PCB exposure [Lauby-Secretan, et al. 2013]. The deficit 
of melanoma in the Massachusetts subcohort might be related to its ethnic composition; an 
estimated 30% are of Portuguese or Cape Verdean ethnicity with darker skin pigmentation, 
which is a protective factor for melanoma [Fortes and de Vries 2008]. 
Breast, ovarian, uterine and prostate cancer are among those cancers associated with 
hormonal factors, and endocrine disruptors such as polychlorinated biphenyls [National Research 
Council 2000] may modify risk.  For each of these categories of disease there are additional 
demographic risk factors which can affect the results, such as shift work, family history, 
ethnicity, parity and reproductive history [Poole, et al. 2011; Silver, et al. 2009].  In this analysis, 
which did not include demographic risk factors, we did not see increased risk of breast cancer.  
However, our nested case-control study of breast cancer, which adjusted for those risk factors, 
did find increased risk among women of races other than Caucasian [Silver, et al. 2009].  
Compared to the lowest exposure quartile, ovarian cancer mortality was elevated in categories of 
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higher estimated cumulative PCB exposure, but there was no trend of increasing risk with 
increasing exposure, while we observed increasing standardized rates of uterine cancer mortality 
across quartiles of estimated cumulative PCB exposure (Table 6).  There are recognized 
reproductive and hormonal risk factors for these cancers but few strong occupational associations 
[Slack, et al. 2012]. 
The significantly increased risk of prostate cancer in the  highest quartile of estimated 
cumulative PCB exposure (Table 6) and in the Poisson regression analysis (Table 7) support the 
association of  PCB exposure and  increased prostate cancer mortality observed in other cohorts 
[Charles, et al. 2003; Pesatori, et al. 2013].  Our previous analyses showed this association 
among  the more highly exposed Massachusetts and New York workers [Prince, et al. 2006], but 
not the Indiana workers [Ruder, et al. 2006]. 
Stomach cancer mortality was not elevated in the cohort although we observed significant 
trends with increasing estimated cumulative PCB exposure in SRR and Poisson regression 
analyses.  Poisson regression models of stomach cancer, however, were influenced by widely 
varying background rates.  When the model intercept was constrained to avoid implausibly low 
background rates, both of these rate ratios were diminished, but remained statistically significant.  
Park and colleagues [Park, et al. 2012] similarly observed implausibly low model intercepts in 
some Poisson regression models of the lung cancer SMR in a cohort of workers exposed to 
cadmium and arsenic; to account for this, they additionally reported rate ratios adjusted to a 
common unexposed SMR of 0.8.  In our study, when workers potentially exposed to TCE were 
excluded from the analysis, the stomach cancer rate ratio was attenuated (but remained 
statistically significant), indicating that some of the increased risk was due to confounding by 
TCE exposure.  TCE exposure was associated with stomach cancer in one cohort study of TCE-
18 
exposed workers [Anttila, et al. 1995] but not in others [Blair, et al. 1998; Boice, et al. 2006].  
Our Poisson models would have been more robust if the numbers of deaths had been larger; this 
limitation could be alleviated for outcomes with long survival using a cancer incidence study.   
There were some major differences between male and female workers in our cohort.  
Generally the men exhibited the “healthy worker effect”, while the women did not (Table 5). It 
has been noted that working and general populations of women differ in risk factors [Bond, et al. 
1987] and female and male employees in the same industry may have different tasks even if they 
have the same job title [Stellman 1999]. The observed mortality differences between male and 
female workers may be due to differences in work assignments, differences in physiology, and 
differences in how their bodies reacted to PCBs [Eng, et al. 2011; Messing and Mager Stellman 
2006; Silvaggio and Mattison 1994].  Since various PCB congeners have estrogenic, anti-
estrogenic, androgenic or anti-androgenic properties [Diamanti-Kandarakis, et al. 2009], it 
follows that female-male hormonal differences might be associated with the activity of PCBs in 
the body [Meeker and Hauser 2010; Salehi, et al. 2008].   
Our a priori causes of interest, based on several case-control studies, included non-
Hodgkin lympohoma [Engel, et al. 2007; Rothman, et al. 1997].  However, we did not find an 
increase in NHL mortality nor an association between NHL and estimated cumulative exposure.  
The findings of our cohort mortality study differed from those of the case-control studies of NHL 
incidence.  This discrepancy may be due to differences in the study populations and the outcome 
variable (death vs diagnosis).   
We did not find excesses for other a priori outcomes (rectal cancer, biliary passages, 
liver, and gall bladder cancer, or thyroid cancer).  The cancer incidence study we are conducting 
on this combined cohort may provide some additional insight, particularly for cancers with high 
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survival rates such as thyroid cancer [National Cancer Institute 2011].  
A strength of this combined cohort mortality update study is the detailed exposure 
assessment.  The data  available to construct the job-exposure matrices included individual work 
histories, detailed job descriptions for hourly jobs, and exp sets of exposure measurements 
collected at the plants [Hopf, et al. 2013; Hopf, et al. 2009b; Hopf, et al. 2010].  However, as in 
most records-based retrospective occupational cohort studies, we had no information on risk 
factors explored in case-control studies, such as family history or genetic susceptibility; lifestyle 
choices, such as smoking or sun exposure, that could affect mortality; or on previous or 
subsequent employment. 
This last limitation is significant because a majority of cohort members worked a year or 
less at one of the plants (Table 2).  Increased mortality among short-term workers has been 
reported, particularly for causes of death associated with disorders that might affect employment 
or with an unhealthy lifestyle. Those who are only briefly in a workplace might leave because of 
sensitization to work materials, and possibly the beginning of work-related chronic conditions 
[Langseth and Kjaerheim 2006], or shorter durations of employment might be associated with 
more pre-employment hospitalizations for alcohol use, accidents, and the effects of violence 
[Kolstad and Olsen 1999].  We have no lifestyle or hospitalization information for our cohort.  
However, our analyses showed different mortality profiles for short-term and long-term workers, 
as have been found in other studies [Boffetta, et al. 1998; Kolstad and Olsen 1999]. Significant 
excess mortality from all cancers, digestive and respiratory cancers, and HIV-related diseases 
were seen among the third of the cohort that worked fewer than three months.  Among long-term 
workers only the excess of melanoma deaths was statistically significant. These differences 
could be due to lifestyle differences as well as differences in occupational exposure or 
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physiological reactions to that exposure. 
In conclusion, we found evidence of associations between employment in capacitor 
manufacturing and increased total cancer and intestinal cancer mortality among female long-term 
workers and excess melanoma mortality for male long-term workers.  The associations in our life 
table analyses convey moderate increased risk.  We did not observe increased risk for several a 
priori causes of death for which case-control studies observed increased risk. The internal 
comparisons show increasing risk with estimated cumulative exposure for uterine, prostate and 
stomach cancer, and multiple myeloma.   
Thirty-five years after PCB use was banned, the former workers in our cohort continue to 
be exposed internally to PCBs.  Occupational and environmental exposure also continues for 
those who repair, maintain, or remove capacitors and transformers containing PCBs and for the 
general public, emphasizing the continued importance of understanding health risks associated 
with PCB exposures. 
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Table 1 
Differences among the three capacitor manufacturing plants in the NIOSH capacitor cohort 
 
Determinant Indiana New York Massachusetts 
Chemicalsa Aroclor 1254 use -- 1946-1955 b 1939-1958 c 
Aroclor 1242 use ~1958-1971 1955-1971 1958-1976 
Aroclor 1016 use 1971-1977 1971-1977 
 
1976-~1977 
Other Aroclors Yes – (detected by EPA 
around the plant where used 
oil was dumped): Aroclors 
1248, 1254, and 1260  
Yes – occasional use of 
Aroclor 1221 (50% mono-
Cl + 35% di-Cl + 5% tri and 
tetra Cl) 1971-1975 
No 
Dielectric fluids other than 
PCBs 
No Yes after 1977: Bis(2-
ethylhexyl) phthalate 
(DEHP), castor oil, and 
mineral oil 
Yes – castor oil and mineral 
oils used in large capacitors 
Degreasing solvent TCE TCE, detergent from 1977 TCE, degreasing station 
often leaked  
Process 
description 
Method of filling capacitors 
with PCBs 
Manual 
 
Manual 1946-1960; some 
automation after 1960 
Flood filling temperatures 
>100°C 
Manual 
 
Process changes over time Yes, but timing and nature 
of change unknown 
 Few changes Very few changes made 
from 1947-1977 
Plant-specific 
information 
Years of operation using 
Aroclors 
1958-1977 1946-1977 1939-1977 
Ventilation Leakage of oil mist from 
impregnation chambers 
because the oil seal was 
broken 
Local exhaust ventilation 
provided but often not used 
Insufficient duct size in 
chamber filling area 
Degreaser leaked TCE, 
open tanks 
Exhaust vapors re-entered 
work area  
Painting booths not 
equipped with ventilation 
General dilution ventilation 
iInstalled in 1965; upgrade 
in 1976  reduced exposures 
75% from 1976 to 1977 
No local ventilation for 
oven opening – PCBs were 
exhausted from the 
impregnation ovens by 
opening the doors 
Personal protective 
equipment 
Respirators provided but no 
training or change out 
schedule – mostly not used 
by the workers 
Not documented Not documented 
Plant lay-out 1968 expansion of plant 
with new non-PCB 
production areas 
Very small area of the plant 
dedicated to manufacturing 
with PCBs 
Two different facilities 
Frequent changes 
Large spills at both facilities 
frequent due to the set-up of 
the manufacturing process. 
Impregnation on 1st and 2nd 
floors 
Capacitors were moved 
from department to 
department and from floor 
to floor 
PCB areas not physically 
separated  
Manufacture of items other 
than PCB-filled capacitors 
Yes – manufactured shunt 
capacitors, series capacitors, 
lighting arresters, reclosers 
and breakers, switches, 
potential devices, and line 
traps 
No Yes – produced mica and 
tubular capacitors 
Exposure category values 
used in job-exposure matrix 
High 
Medium 
Low 
Baseline 
[Hopf, et al. 2009b] 
 
230 
140 
50 
5 
[Hopf, et al. 2013] 
 
750 
300 
50 
10 
[Hopf, et al. 2010] 
 
770 
550 
180 
50 
27 
Abbreviations: PCB, polychlorinated biphenyl; TCE, trichloroethylene 
a          When plants changed from one Aroclor product to another, the substitution process was gradual over several 
months during which more 
       than one product would be in use. 
b Different periods of use of various Aroclors have been reported:  Aroclor 1254 from 1946-1954 and Aroclor 
1242 from 1954-1971 [Taylor, et al. 1991]; Aroclor  1016 from 1971-1976 [Jones, et al. 1978; Taylor, et al. 
1991]; occasional use of Aroclor 1221  [Jones, et al. 1978]. 
c Date of switch from Aroclor 1254 to Aroclor 1242 is uncertain. 
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Table 2 
Cohort demographics and vital status as of December 31, 2008, NIOSH Capacitor Cohort 
 
Characteristic Entire cohort 
Plant 
Indiana 
(1957-1977) 
Massachusetts 
(1938-1976) 
New York 
(1946-1977) 
Total workers 25,062 3,601 12,616 8,845 
Excluded from analysis a 197 21 58 118 
Total analyzed 24,865 3,580 12,558 8,727 
Vital status b     
Dead 8,749 (35%) 1,021 (29%) 4,489 (36%) 3,239 (37%) 
Alive 15,356 (62%) 2,479 (69%) 7,591 (60%) 5,286 (61%) 
Lost to follow-up 760 (3%) 80 (2%) 478 (4%) 202 (2%) 
Race, gender     
Caucasian females 6,719 (27%) 555 (16%) 3,832 (31%) 2,332 (27%) 
Females of other races 275 (1%) 19 (<1%) 220 (2%) 36 (<1%) 
Race-unknown females c 6,083 (24%) 282 (8%) 4,377 (35%) 1,424 (16%) 
Caucasian males 2,171 (9%) 517 (14%) 787 (6%) 867 (10%) 
Males of other races 42 (<1%) 11 (<1%) 25 (<1%) 6 (<1%) 
Race-unknown males c 9,575 (39%) 2,196 (61%) 3,317 (26%) 4,062 (47%) 
Age at first employment (years)     
Median (interquartile range) 22.4 (18.7-29.7) 24.2 (20.9-31.4) 19.7 (17.4-27.5) 24.4 (21.0-31.1) 
Mean ± standard deviation 25.6 ± 9.1 27.0 ± 8.2 24.1 ± 9.7 27.1 ± 8.3 
Duration of employment (years)     
Median  (interquartile range) 0.77 (0.18-4.0) 1.26 (0.29-5.6) 0.45 (0.11-2.5) 1.20 (0.32-5.8) 
Mean ± standard deviation 3.75 ± 6.33 3.93 ± 5.25 3.12 ± 6.18 4.57 ± 6.83 
Estimated cumulative exposure (unit-days) d     
Unknown 515 22 476 17 
Lowest quartile (0-<10,000) 7423 (30%) 1444 (40%) 3593 (29%) 2386 (27%) 
Second quartile (10,000-<60,000) 7243 (29%) 1116 (31%) 3657 (29%) 2470 (28%) 
Third quartile (60,000-< 400,000) 6091 (24%) 878 (25%) 2850 (23%) 2363 (27%) 
Highest quartile (≥400,000) 3593 (14%) 120 (3%) 1982 (16%) 1491 (17%) 
Person-years at risk     
Sum 1,019,128 138,219 528,572 352,337 
 
a Missing employment dates (n = 124), missing date of birth (n = 72), missing date of death (n = 1). 
b For the analysis, workers lost to follow-up were considered alive until the date lost to follow-up. 
c Race/ethnicity was not available for the majority of cohort members.  For the analysis, race was assumed to be 
Caucasian, based on racial demographics in the geographic areas. 
d Estimated cumulative exposure could not be calculated for 515 workers with periods of unknown exposure 
level.  Cut-points based on quartiles of estimated cumulative exposure for all decedents. 
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Table 3 
Standardized mortality ratios overall and by duration of employment, NIOSH Capacitor Cohort, 1960-2008 a 
 
Underlying cause of death b 
Entire cohort 
(n = 24,865) 
 
Short-term workers c 
(n = 7,647) 
 
Long-term workers c 
(n = 17,218) 
OBS SMR d 95% CI OBS SMR 95% CI OBS SMR 95% CI 
All causes 8688 0.99 0.97-1.01  2255 1.17 1.12-1.22  6433 0.94 0.91-0.96 
All cancers 2593 1.06 1.02-1.10  686 1.20 1.11-1.30  1907 1.01 0.97-1.06 
MN of buccal cavity and pharynx 45 1.12 0.82-1.50  17 1.89 1.10-3.03  28 0.90 0.60-1.29 
MN of tongue 12 1.25 0.65-2.18  3 1.38 0.28-4.02  9 1.21 0.55-2.30 
MN of other parts of buccal cavity 15 1.36 0.76-2.24  4 1.67 0.46-4.28  11 1.27 0.64-2.28 
MN of pharynx 18 0.94 0.56-1.48  10 2.31 1.11-4.25  8 0.54 0.23-1.06 
MN of digestive organs and peritoneum 603 1.09 1.00-1.18  151 1.23 1.04-1.44  452 1.05 0.95-1.15 
MN of esophagus 60 1.21 0.92-1.55  10 0.90 0.43-1.66  50 1.29 0.96-1.71 
MN of stomach 58 1.04 0.79-1.35  12 1.01 0.52-1.77  46 1.05 0.77-1.40 
MN of intestine except rectum 231 1.11 0.97-1.27  56 1.23 0.93-1.60  175 1.08 0.92-1.25 
MN of rectum 50 1.21 0.90-1.59  9 0.98 0.45-1.85  41 1.27 0.91-1.73 
MN of biliary passages, liver and gall bladder 63 0.98 0.76-1.26  19 1.29 0.78-2.01  44 0.89 0.65-1.20 
MN of pancreas 136 1.08 0.90-1.28  42 1.47 1.06-1.98  94 0.96 0.78-1.18 
MN of peritoneum and other and unspecified of digestive organs 5 0.53 0.17-1.24  3 1.40 0.29-4.10  2 0.27 0.03-0.99 
MN of respiratory system 797 1.08 1.00-1.15  230 1.35 1.19-1.54  567 0.99 0.91-1.08 
MN of larynx 24 1.32 0.85-1.97  8 2.04 0.88-4.02  16 1.13 0.64-1.83 
MN of trachea, bronchus, and lung 766 1.07 0.99-1.15  221 1.34 1.17-1.53  545 0.99 0.91-1.07 
MN other parts of respiratory system 7 1.52 0.61-3.14  1 0.91 0.02-5.09  6 1.71 0.63-3.72 
MN of breast 239 1.01 0.89-1.15  74 1.15 0.90-1.44  165 0.96 0.82-1.12 
MN of female genital organs 143 1.00 0.84-1.18  39 1.03 0.73-1.41  104 0.99 0.81-1.20 
MN of cervix uteri 31 1.12 0.76-1.60  10 1.29 0.62-2.37  21 1.06 0.66-1.62 
MN of other and unspecified parts of uterus 34 1.07 0.74-1.50  6 0.75 0.28-1.63  28 1.18 0.78-1.70 
MN of ovary, fallopian tube, and broad ligament 69 0.88 0.68-1.11  20 0.96 0.59-1.48  49 0.85 0.63-1.13 
MN of other female genital organs 9 1.75 0.80-3.32  3 2.38 0.49-6.95  6 1.54 0.57-3.36 
MN of male genital organs 87 0.96 0.77-1.18  9 0.57 0.26-1.09  78 1.04 0.82-1.30 
MN of prostate 87 0.99 0.80-1.23  9 0.61 0.28-1.16  78 1.07 0.85-1.34 
MN of urinary organs 109 1.08 0.89-1.31  31 1.43 0.97-2.02  78 0.99 0.78-1.24 
MN of kidney 56 1.03 0.78-1.34  14 1.12 0.61-1.88  42 1.01 0.73-1.36 
MN of bladder and other urinary organs 53 1.15 0.86-1.50  17 1.84 1.07-2.95  36 0.97 0.68-1.35 
MN of other and unspecified sites 335 1.06 0.95-1.18  80 1.06 0.84-1.32  255 1.06 0.94-1.20 
MN of bone 6 1.12 0.41-2.44  3 2.25 0.46-6.59  3 0.75 0.15-2.18 
Melanoma 47 1.20 0.88-1.60  6 0.60 0.22-1.30  41 1.41 1.01-1.91 
Other MN of skin 9 0.93 0.42-1.76  4 1.87 0.51-4.78  5 0.66 0.21-1.54 
Mesothelioma 7 1.53 0.61-3.15  1 0.94 0.02-5.26  6 1.70 0.62-3.71 
MN of connective tissue 14 0.94 0.51-1.57  3 0.78 0.16-2.27  11 0.99 0.50-1.77 
MN of brain and other parts of nervous system 67 1.01 0.78-1.28  14 0.83 0.45-1.39  53 1.07 0.80-1.40 
MN of thyroid gland 3 0.52 0.11-1.53  0 0.00 0.00-2.76  3 0.68 0.14-2.00 
MN of other and unspecified sites 181 1.07 0.92-1.24  49 1.27 0.94-1.68  132 1.02 0.85-1.21 
Neoplasms of lymphatic and hematopoietic tissue 235 1.01 0.88-1.15  55 1.02 0.77-1.33  180 1.01 0.86-1.16 
Hodgkin disease 9 0.76 0.35-1.45  4 1.28 0.35-3.27  5 0.58 0.19-1.35 
Non-Hodgkin lymphoma 93 0.99 0.80-1.21  24 1.11 0.71-1.65  69 0.95 0.74-1.20 
Multiple myeloma 45 1.12 0.82-1.50  4 0.45 0.12-1.14  41 1.31 0.94-1.78 
Leukemia and aleukemia 88 1.02 0.82-1.25  23 1.15 0.73-1.73  65 0.98 0.75-1.24 
Benign and unspecified neoplasms 30 0.90 0.61-1.29  9 1.19 0.54-2.25  21 0.82 0.51-1.26 
Tuberculosis and HIV-related disease 47 1.23 0.91-1.64  32 2.80 1.91-3.95  15 0.56 0.32-0.93 
Respiratory tuberculosis 3 0.47 0.10-1.36  1 0.81 0.02-4.50  2 0.38 0.05-1.39 
HIV-related 44 1.45 1.06-1.95  31 3.13 2.13-4.44  13 0.64 0.34-1.09 
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Diseases of the blood and blood forming organs 32 0.89 0.61-1.25  3 0.38 0.08-1.12  29 1.02 0.69-1.47 
Diabetes mellitus 206 0.91 0.79-1.04  54 1.05 0.79-1.36  152 0.87 0.74-1.02 
Mental, psychoneurotic, and personality disorders 113 0.84 0.69-1.01  39 1.40 0.99-1.91  74 0.69 0.54-0.87 
Alcoholism 19 0.60 0.36-0.94  10 1.20 0.58-2.21  9 0.39 0.18-0.74 
Other mental disorders 94 0.91 0.74-1.12  29 1.48 0.99-2.12  65 0.78 0.60-0.99 
Dementia and Alzheimer disease e 116 1.04 0.86-1.24  32 1.57 1.08-2.22  84 0.92 0.73-1.14 
Disorders of the nervous system and sense organs 254 1.09 0.96-1.24  60 1.22 0.93-1.57  194 1.06 0.92-1.22 
Multiple sclerosis 14 0.91 0.50-1.53  3 0.68 0.14-1.98  11 1.01 0.50-1.81 
Other diseases of the nervous system and sense organs 240 1.11 0.97-1.26  57 1.27 0.96-1.65  183 1.07 0.92-1.23 
Amyotrophic lateral sclerosis e 31 1.34 0.91-1.90  11 1.95 0.97-3.50  20 1.14 0.70-1.76 
Parkinson disease e 45 1.14 0.83-1.52  3 0.42 0.09-1.22  42 1.30 0.94-1.76 
Diseases of the heart 2520 0.96 0.92-1.00  593 1.14 1.05-1.23  1927 0.92 0.87-0.96 
Rheumatic heart disease, including fever 28 0.71 0.47-1.03  6 0.71 0.26-1.55  22 0.71 0.45-1.08 
Hypertension with heart disease 60 0.71 0.54-0.92  19 1.07 0.65-1.68  41 0.62 0.44-0.84 
Ischemic heart disease 1984 0.96 0.92-1.01  454 1.12 1.02-1.23  1530 0.92 0.88-0.97 
Chronic disease of endocardium 44 0.87 0.63-1.17  7 0.69 0.28-1.42  37 0.91 0.64-1.26 
Cardiomyopathy 86 1.08 0.86-1.33  27 1.50 0.99-2.18  59 0.96 0.73-1.23 
Conduction disorder 148 1.08 0.91-1.27  42 1.46 1.05-1.98  106 0.98 0.80-1.19 
Other diseases of the heart 170 0.98 0.84-1.14  38 1.12 0.79-1.54  132 0.95 0.79-1.12 
Other diseases of the circulatory system 734 0.96 0.89-1.03  136 0.89 0.74-1.05  598 0.98 0.90-1.06 
Cerebrovascular disease 478 0.94 0.85-1.02  89 0.88 0.71-1.09  389 0.95 0.86-1.05 
Hypertension without heart disease 43 0.96 0.69-1.29  3 0.32 0.07-0.95  40 1.12 0.80-1.53 
Diseases of the arteries, veins and lymphatic vessel 213 1.02 0.88-1.16  44 1.02 0.74-1.37  169 1.02 0.87-1.18 
Diseases of the respiratory system 725 0.98 0.91-1.06  196 1.29 1.11-1.48  529 0.91 0.83-0.99 
Influenza 3 0.59 0.12-1.73  0 0.00 0.00-3.67  3 0.74 0.15-2.15 
Pneumonia (except newborn) 213 1.07 0.93-1.23  51 1.32 0.98-1.74  162 1.01 0.86-1.18 
Chronic obstructive pulmonary disease  400 1.00 0.91-1.10  118 1.40 1.16-1.68  282 0.90 0.79-1.01 
Asthma 16 0.97 0.55-1.57  6 1.47 0.54-3.21  10 0.80 0.38-1.47 
Other respiratory diseases 89 0.81 0.65-1.00  21 0.90 0.56-1.38  68 0.78 0.61-0.99 
Diseases of the digestive system 320 0.85 0.76-0.95  96 1.11 0.90-1.36  224 0.78 0.68-0.89 
Diseases of the skin and subcutaneous tissue 8 0.75 0.32-1.48  0 0.00 0.00-1.58  8 0.96 0.41-1.89 
Diseases of the musculoskeletal system and connective system 33 0.85 0.58-1.19  10 1.09 0.52-2.00  23 0.78 0.49-1.16 
Diseases of the genito-urinary system 136 0.89 0.75-1.05  34 1.08 0.74-1.50  102 0.84 0.69-1.02 
Chronic and unspecified nephritis and renal failure and other renal 
sclerosis 90 1.12 0.90-1.38  25 1.46 0.95-2.16  65 1.03 0.80-1.32 
Symptoms and ill-defined conditions 45 0.52 0.38-0.70  16 0.79 0.45-1.29  29 0.44 0.29-0.63 
Transportation injuries 167 0.78 0.66-0.91  60 0.94 0.72-1.21  107 0.71 0.58-0.86 
Falls 39 0.70 0.50-0.96  2 0.17 0.02-0.61  37 0.85 0.60-1.17 
Other injury 120 0.79 0.66-0.95  49 1.19 0.88-1.57  71 0.65 0.50-0.81 
Intentional self-harm 110 0.73 0.60-0.88  39 0.92 0.66-1.26  71 0.66 0.51-0.83 
Assault and homicide 23 0.44 0.28-0.67  13 0.82 0.44-1.40  10 0.28 0.13-0.51 
Other causes 207 0.91 0.79-1.04  64 1.17 0.70-1.49  143 0.82 0.69-0.97 
Unknown cause 226    64    162   
 
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; OBS, observed deaths; MN, 
malignant neoplasm; SMR, standardized mortality ratio. 
 
a All results exclude workers who died (n = 61) or were lost to follow-up (n = 324) prior to the rate file begin date 
(1 January 1960). 
b International Classification of Disease (ICD) codes were mapped to underlying cause of death categories as 
described by Robinson et al. (2006) and tabulated on the NIOSH website 
(http://www.cdc.gov/niosh/ltas/rates.html).  All major categories of causes of death are presented.  Some minor 
categories of causes of death are not presented because there were two or fewer deaths in the category or the 
category was not of a priori interest and the SMR was not in statistically significant excess. 
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c Short-term workers worked less than 3 months; long-term workers worked 3 months or longer. 
d The SMR is the ratio of observed to expected (based on US underlying cause of death rates, 1960-2007) deaths; 
95% CI was estimated based on the Poisson distribution.   
e Neurodegenerative outcomes based on US underlying cause of death rates, 1960-2007.  Dementia and 
Alzheimer disease (excluding arteriosclerotic dementia) includes ICD codes 304-305 (revision 7), 290.0-290.1 
(revision 8), 290.0-290.3 and 331.0 (revision 9), and G30 (revision 10); amyotrophic lateral sclerosis includes 
ICD codes 306 (revision 7), 348.0 (revision 8), 335.2 (revision 9), and F01 (revision 10); and Parkinson disease 
includes ICD codes 350 (revision 7), 342 (revision 8), 332 (revision 9), and G20-G21 (revision 10). 
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Table 4 
Standardized mortality ratios for outcomes of a priori interest among long-term workers (3 months or longer) by 
plant, NIOSH Capacitor Cohort, 1960-2008 a 
 
Underlying cause of death b 
Indiana plant 
(n = 2,794) 
 
Massachusetts plant 
(n = 7,499) 
 
New York plant 
(n = 6,925) 
OBS SMR c 95% CI OBS SMR 95% CI OBS SMR 95% CI 
All causes 800 0.79 0.73-0.84  2998 1.02 0.98-1.05  2635 0.92 0.89-0.96 
All cancers 246 0.83 0.73-0.94  860 0.99 0.92-1.05  801 1.02 0.95-1.09 
MN of stomach 4 0.73 0.20-1.87  28 1.26 0.83-1.81  14 0.59 0.32-0.99 
MN of intestine except rectum 21 0.85 0.53-1.30  80 1.01 0.80-1.25  74 0.98 0.77-1.23 
MN of rectum 2 0.43 0.05-1.55  15 0.86 0.48-1.41  24 1.52 0.97-2.26 
MN of biliary passages, liver and gall bladder 5 0.7 0.23-1.63  22 1.05 0.66-1.59  17 0.77 0.45-1.24 
MN of breast 8 0.64 0.28-1.26  99 0.91 0.74-1.11  58 0.86 0.65-1.11 
MN of other and unspecified parts of uterus 0 0 0-2.11  18 1.22 0.72-1.93  10 1.09 0.52-2.01 
MN of ovary, fallopian tube, and broad ligament 1 0.24 0.01-1.34  34 0.99 0.69-1.39  14 0.65 0.36-1.09 
MN of prostate 9 0.62 0.28-1.18  25 1.08 0.70-1.59  44 1.25 0.91-1.68 
Melanoma 13 2.58 1.38-4.42  8 0.63 0.27-1.24  20 1.71 1.04-2.64 
MN of brain and other parts of nervous system 17 2.06 1.20-3.29  18 0.93 0.55-1.47  18 0.98 0.58-1.55 
MN of thyroid 1 1.71 0.04-9.52  1 0.49 0.01-2.72  1 0.49 0.01-2.74 
Non-Hodgkin lymphoma 11 0.94 0.47-1.67  39 1.23 0.87-1.68  19 0.6 0.36-0.94 
Multiple myeloma 2 0.4 0.05-1.46  18 1.32 0.78-2.09  21 1.74 1.08-2.66 
Dementia and Alzheimer disease d 2 0.24 0.03-0.85  46 0.99 0.73-1.32  36 0.98 0.69-1.36 
Amyotrophic lateral sclerosis d 2 0.72 0.09-2.59  8 1.07 0.46-2.11  10 1.37 0.66-2.53 
Parkinson disease d 5 1.14 0.37-2.67  16 1.17 0.67-1.89  21 1.48 0.91-2.26 
 
Abbreviations: CI, confidence interval; OBS, observed deaths; MN, malignant neoplasm; SMR, standardized 
mortality ratio. 
 
a All results are for long-term workers (employed for 3 months or longer) and exclude workers who died (n = 58) 
or were lost to follow-up (n = 155) prior to the rate file begin date (1 January 1960).   
b For cause of death outcomes of a priori interest.  Complete results available from the first author. 
c The SMR is the ratio of observed to expected deaths (based on state-specific underlying cause of death rates, 
1960-2007); 95% CI was estimated based on the Poisson distribution.   
d Neurodegenerative outcomes based on US underlying cause of death rates, 1960-2007. 
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Table 5 
Standardized mortality ratios for outcomes of a priori interest among long-term workers (3 months or longer) by 
sex, NIOSH Capacitor Cohort, 1960-2008 a 
 
Underlying cause of death b 
Women 
(n = 8,642) 
 
Men 
(n = 8,576) 
OBS SMR c 95% CI OBS SMR 95% CI 
All causes 3155 0.97 0.94-1.01  3278 0.91 0.88-0.94 
All cancers 983 1.06 1.00-1.13  924 0.97 0.90-1.03 
MN of stomach 13 0.75 0.40-1.28  33 1.25 0.86-1.75 
MN of intestine except rectum 102 1.23 1.00-1.49  73 0.92 0.72-1.16 
MN of rectum 22 1.52 0.95-2.30  19 1.07 0.65-1.67 
MN of biliary passages, liver and gall bladder 25 1.12 0.73-1.65  19 0.70 0.42-1.10 
MN of breast 163 0.96 0.82-1.12  2 1.68 0.20-6.07 
MN of other and unspecified parts of uterus 28 1.18 0.78-1.70     
MN of ovary, fallopian tube, and broad ligaments 49 0.85 0.63-1.13     
MN of prostate     78 1.07 0.85-1.34 
Melanoma 12 1.11 0.57-1.94  29 1.59 1.06-2.28 
MN of brain and other parts of nervous system 19 0.85 0.51-1.33  34 1.25 0.87-1.75 
MN of thyroid 2 0.79 0.10-2.84  1 0.54 0.01-3.04 
Non-Hodgkin lymphoma 37 1.07 0.75-1.48  32 0.84 0.58-1.19 
Multiple myeloma 20 1.30 0.80-2.01  21 1.32 0.82-2.01 
Dementia and Alzheimer disease d 62 0.96 0.73-1.23  22 0.82 0.51-1.24 
Amyotrophic lateral sclerosis d 16 1.90 1.09-3.09  4 0.44 0.12-1.12 
Parkinson disease d 16 1.12 0.64-1.81  26 1.45 0.94-2.12 
 
Abbreviations: CI, confidence interval; OBS, observed deaths; MN, malignant neoplasm; SMR, standardized 
mortality ratio. 
 
a All results are for long-term workers (employed for 3 months or longer) and exclude workers who died (n = 58) 
or were lost to follow-up (n = 155) prior to the rate file begin date (1 January 1960). 
b For cause of death outcomes of a priori interest.  Complete results available from the first author. 
c The SMR is the ratio of observed to expected (using United States underlying cause of death rates, 1960-2007) 
deaths; 95% CI was estimated based on the Poisson distribution . 
d Neurodegenerative outcomes based on US underlying cause of death rates, 1960-2007. 
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Table 6 
Standardized rate ratio analyses among long-term workers (3 months or longer), NIOSH Capacitor Cohort, 1960-
2008  
 
Underlying cause of death a 
Estimated cumulative PCB exposure (unit-days) 
P 
value c 
0-<40,000 
 
40,000-<150,000 
 
150,000-<600,000 
 
≥600,000 
OBS SRRb 95% CI OBS SRR 95% CI OBS SRR 95% CI OBS SRR 95% CI 
All causes 1600 1 [ref]  1467 1.08 1.00-1.17  1531 1.19 1.10-1.28  1547 1.07 0.98-1.17 0.60 
All cancers 511 1 [ref]  462 1.14 1.00-1.29  417 1.10 0.96-1.25  427 1.17 0.98-1.39 0.24 
MN of stomach 4 1 [ref]  6 2.11 0.58-7.67  15 5.14 1.66-15.9  17 8.37 2.52-27.8 <0.001 
MN of intestine except rectum 41 1 [ref]  48 1.42 0.92-2.19  35 1.08 0.68-1.72  43 0.93 0.60-1.45 0.36 
MN of rectum 10 1 [ref]  9 1.11 0.43-2.84  6 0.76 0.26-2.18  14 1.56 0.60-4.02 0.50 
MN of biliary passages, liver and gall 
bladder 11 1 [ref]  9 0.98 0.39-2.48  6 0.76 0.27-2.17  15 1.53 0.66-3.58 0.27 
MN of breast 41 1 [ref]  43 1.24 0.80-1.94  29 0.87 0.53-1.41  39 0.90 0.57-1.42 0.31 
MN of other and unspecified parts of uterus 6 1 [ref]  5 1.06 0.31-3.60  6 1.29 0.40-4.19  9 1.35 0.46-3.98 <0.001 
MN of ovary, fallopian tube, and broad 
ligament 6 1 [ref]  14 3.22 1.19-8.69  9 1.81 0.62-5.26  12 2.31 0.83-6.42 0.40 
MN of prostate 17 1 [ref]  21 1.73 0.90-3.32  14 1.28 0.62-2.64  25 2.11 1.08-4.13 0.14 
Melanoma 21 1 [ref]  5 0.34 0.13-0.92  10 0.78 0.37-1.68  3 0.20 0.06-0.70 0.21 
MN of brain and other parts of nervous 
system 22 1 [ref]  9 0.53 0.24-1.16  13 0.82 0.41-1.64  7 0.58 0.21-1.56 0.67 
Non-Hodgkin lymphoma 17 1 [ref]  23 1.84 0.95-3.55  14 1.23 0.58-2.65  12 1.03 0.44-2.45 0.78 
Multiple myeloma 9 1 [ref]  9 1.02 0.39-2.65  9 1.12 0.43-2.92  12 1.31 0.52-3.32 <0.001 
Dementia and Alzheimer disease 20 1 [ref]  10 0.54 0.25-1.17  16 0.77 0.39-1.51  35 1.29 0.73-2.29 0.13 
Amyotrophic lateral sclerosis 6 1 [ref]  2 0.38 0.08-1.93  5 0.95 0.28-3.18  7 1.44 0.41-5.03 0.22 
Parkinson disease 9 1 [ref]  12 1.68 0.68-4.11  7 0.89 0.32-2.47  11 1.19 0.47-2.98 0.97 
 
Abbreviations: CI, confidence interval; MN, malignant neoplasm; OBS, observed deaths; SRR, standardized rate 
ratio. 
 
a For cause of death outcomes of interest a priori (thyroid cancer was omitted due to small numbers). 
b SRR, comparing mortality rates in higher quartiles with rate in the lowest quartile, obtained by direct 
standardization.  Quartiles based on cumulative PCB exposure among decedents with 90 days or more of 
employment.  
c P value for test of linear trend in the standardized rates. 
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Table 7 
Poisson regression models among long-term workers (3 months or longer) for selected underlying cause of death 
outcomes, NIOSH Capacitor Cohort 
 
Cause of death 
Rate ratio (95% confidence interval) a 
Continuous models b 
 
Categorical models c 
Unconstrained d Constrained d 
Estimated 
cumulative PCB 
exposure 
(unit-years) Unconstrained d Constrained d 
Prostate cancer 2.22 (1.06 to 4.80) 1.73 (1.08 to 2.74)  0 to <77 1 [reference] 1 [reference] 
    77 to <240 1.21 (0.58 to 2.49) 1.20 (0.61 to 2.22) 
    240 to <990 1.27 (0.63 to 2.58) 1.27 (0.67 to 2.27) 
    990 to <3200 1.52 (0.73 to 3.14) 1.51 (0.78 to 2.75) 
    ≥3200 2.30 (1.14 to 4.67) 2.28 (1.24 to 4.00) 
       
Uterine cancer 2.88 (0.62 to 15.2) 1.70 (0.71 to 3.95)  0 to <110 1 [reference] 1 [reference] 
    110 to <380 1.05 (0.30 to 3.51) 1.08 (0.34 to 2.93) 
    380 to <880 1.68 (0.48 to 5.62) 1.72 (0.55 to 4.59) 
    880 to <2500 1.28 (0.36 to 4.44) 1.32 (0.41 to 3.59) 
    ≥2500 1.30 (0.35 to 4.67) 1.34 (0.40 to 3.80) 
       
Ovarian cancer 1.07 (0.96 to 1.15) 1.08 (0.98 to 1.16)  0 to <120 1 [reference] 1 [reference] 
    120 to <250 3.29 (1.26 to 9.08) 3.47 (1.46 to 7.89) 
    250 to <870 1.52 (0.54 to 4.36) 1.61 (0.64 to 3.75) 
    870 to <3200 1.49 (0.52 to 4.32) 1.57 (0.61 to 3.74) 
    ≥3200 2.57 (0.89 to 7.60) 2.71 (1.03 to 6.58) 
       
Stomach cancer 4.79 (1.83 to 13.3) 1.99 (1.05 to 3.71)  0 to <110 1 [reference] 1 [reference] 
    110 to <650 1.48 (0.54 to 4.03) 0.95 (0.39 to 2.09) 
    650 to <1000 7.07 (2.66 to 19.0) 4.43 (1.91 to 9.41) 
    1000 to <2100 5.13 (1.98 to 13.6) 3.20 (1.43 to 6.67) 
    ≥2100 3.04 (1.11 to 8.42) 1.88 (0.80 to 4.07) 
       
Multiple myeloma 1.09 (0.99 to 1.17) 1.09 (0.99 to 1.17)  0 to <54 1 [reference] 1 [reference] 
    54 to <170 1.19 (0.42 to 3.45) 1.28 (0.49 to 3.11) 
    170 to <980 0.78 (0.28 to 2.26) 0.84 (0.33 to 2.02) 
    980 to <3300 1.27 (0.46 to 3.66) 1.37 (0.54 to 3.27) 
    ≥3300 1.46 (0.48 to 4.47) 1.59 (0.57 to 3.96) 
 
a Rate ratios are adjusted for age and birth year; rate ratios for stomach cancer are additionally adjusted for 
gender.  All models incorporate the best-fitting (based on model AIC) exposure lag period: 20 years for 
prostate, 10 years for uterine, 5 years for ovarian, 15 years for stomach, and 10 years for multiple myeloma. 
b For continuous model, the rate ratio is at 1000 unit-years of lagged exposure and based on the regression model 
with the best-fitting (based on model AIC) exposure transformation: natural logarithm (prostate, uterine, and 
stomach cancers) and identity (ovarian cancer and multiple myeloma).   
c For categorical models, cutpoints were selected based on quintiles of the lagged exposure distribution among 
cases. 
d The unexposed baseline rate (or low exposed for the categorical model) was either unconstrained or constrained 
to be 180 deaths per 100,000 for prostate cancer, 17 deaths per 100,000 for uterine cancer, 31 deaths per 
100,000 for ovarian cancer, 30 deaths per 100,000 for stomach cancer, and 19 deaths per 100,000 for multiple 
myeloma, respectively. 
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Figure 1 
Poisson regression models with lagged cumulative exposure (unit-years) among long-term workers.  Rate ratios are 
adjusted for age and year of birth for prostate, uterine, and ovarian cancer, and for gender, age, and year of birth for 
stomach cancer and multiple myeloma.  Cumulative exposure for the cases, indicated by the cross-hatches on the 
horizontal axis, was truncated at 5000 unit-years for 7 prostate, 3 uterine, 5 ovarian, 3 stomach, and 3 multiple 
myeloma cases.  Black lines indicate categorical treatment of cumulative exposure and dashed curves indicate 
identity (cyan), natural log (blue), square root (magenta), and restricted cubic spline (orange) transformations.   
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